Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria

Pediatric Blood and Cancer

Volumn 60, Issue 10, 2013, Pages 1574-1581

  Rossig, C ^a   Juergens, H ^a   Schrappe, M ^b   Moericke, A ^b   Henze, G ^c   von Stackelberg, A ^c   Reinhardt, D ^d   Burkhardt, B ^a,e   Woessmann, W ^e   Zimmermann, M ^d   Gadner, H ^f   Mann, G ^f   Schellong, G ^a   Mauz Koerholz, C ^g   Dirksen, U ^a   Bielack, S ^h   Berthold, F ⁱ   Graf, N ^j   Rutkowski, S ^k   Calaminus, G ^a   Kaatsch, P ^l   Creutzig, U ^a,d   more..

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^h OLGAHOSPITAL   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j SAARLAND UNIVERSITY   (Germany)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

more..

Author keywords

Chemotherapy; Childhood cancer; Hematological malignancies; Solid tumors; Targeted therapies; Treatment optimization studies

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; AUSTRIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG MEGADOSE; EWING SARCOMA; GERMANY; HODGKIN DISEASE; HUMAN; MEDULLOBLASTOMA; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL;

CHEMOTHERAPY; CHILDHOOD CANCER; HEMATOLOGICAL MALIGNANCIES; SOLID TUMORS; TARGETED THERAPIES; TREATMENT OPTIMIZATION STUDIES;

ADOLESCENT; AUSTRIA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT; MALE; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; REGISTRIES; SURVIVAL RATE;

EID: 84881484546     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24598     Document Type: Article

References (98)

1. Steliarova-Foucher E, Kaatsch P, Lacour B, et al. Quality, comparability, methods of analysis of data on childhood cancer in Europe, (1978-1997): Report from the ACCIS project. Eur J Cancer 2006; 42:1915-1951.
2. Kaatsch P, Spix J. German Childhood Cancer Registry-Annual Report, 2011 (1980-2010). www.kinderkrebsregister.de. Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University, Mainz, 2012.
3. George P, Hernandez K, Hustu O, et al. A study of "total therapy" of acute lymphocytic leukemia in children. J Pediatr 1968; 72:399-408.
4. Lampert F. Results of Memphis-study VII ("Pinkel-Therapy") in 659 children with acute lymphoblastic leukemia. Cooperative therapeutic study of the F German working group on childhood leukemia with participation of 42 hospitals. Klin Padiatr 1978; 190:57-64.
5. Henze G, Langermann HJ, Lampert F, et al. ALL therapy study, 1971-1974 of the German working group for leukemia research and therapy in childhood: Prognostic significance of initial features and different therapeutic modalities. Klin Padiatr 1979; 191:114-126.
6. Riehm H, Gadner H, Welte K. The West-Berlin therapy study of acute lymphoblastic leukemia in childhood-Report after 6 years. Klin Padiatr 1977; 189:89-102.
7. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from, 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000; 14:2205-2222.
8. Koscielniak E, Jurgens H, Winkler K, et al. Treatment of soft tissue sarcoma in childhood, adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study. Cancer 1992; 70:2557-2567.
9. Gobel U, Schneider DT, Calaminus G, et al. Germ-cell tumors in childhood, adolescence. GPOH MAKEI, the MAHO study groups. Ann Oncol 2000; 11:263-271.
10. Gadner H, Heitger A, Ritter J, et al. Langerhans cell histiocytosis in childhood-Results of the DAL-HX 83 study. Klin Padiatr 1987; 199:173-182.
11. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from, 1981 to 2000. Leukemia 2010; 24:265-284.
12. Henze G, Langermann HJ, Bramswig J, et al. The BFM 76/79 acute lymphoblastic leukemia therapy study. Klin Padiatr 1981; 193:145-154.
13. Henze G, Langermann HJ, Fengler R, et al. Acute lymphoblastic leukemia therapy study BFM 79/81 in children, adolescents: Intensified reinduction therapy for patients with different risk for relapse. Klin Padiatr 1982; 194:195-203.
14. Hustu HO, Aur RJ, Verzosa MS, et al. Prevention of central nervous system leukemia by irradiation. Cancer 1973; 32:585-597.
15. Schrappe M, Reiter A, Henze G, et al. Prevention of CNS recurrence in childhood ALL: Results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Klin Padiatr 1998; 210:192-199.
16. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children, adolescents with B-cell precursor acute lymphoblastic leukemia: Results in, 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115:3206-3214.
17. Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82, 85, 89, 92, 97. Leukemia 2010; 24:298-308.
18. Schrauder A, von Stackelberg A, Schrappe M, et al. Allogeneic hematopoietic SCT in children with ALL: Current concepts of ongoing prospective SCT trials. Bone Marrow Transplant 2008; 41:S71-S74.
19. Creutzig U, Ritter J, Riehm H, et al. Improved treatment results in childhood acute myelogenous leukemia: A report of the German cooperative study AML-BFM-78. Blood 1985; 65:298-304.
20. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies, long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19:2030-2042.
21. Reinhardt D, von Neuhoff C, Sander A, Creutzig U. Genetic prognostic factors in childhood acute myeloid leukemia. Klin Padiatr 2012; 224:153-155.
22. Creutzig U, Zimmermann M, Dworzak M, Ritter J, Schellong G, Reinhardt D. Development of a curative treatment within the AML-BFM studies. Klin Padiatr 2013, in press.
23. Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine, mitoxantrone: Different impact on pediatric AML patients with t(8:21), with inv(16). Blood 2011; 118:5409-5415.
24. Klusmann JH, Reinhardt D, Zimmermann M, et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: Results from the AML-BFM 98 study. Haematologica 2012; 97:21-29.
25. Sander A, Zimmermann M, Dworzak M, et al. Consequent, intensified relapse therapy improved survival in pediatric AML: Results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24:1422-1428.
26. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths, treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93, A ML-BFM 98. J Clin Oncol 2004; 22:4384-4393.
27. Creutzig U, Ritter J, Zimmermann M, Schellong G. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. Clin J Oncol 1993; 11:279-286.
28. Creutzig U, Zimmermann M, Bourquin JP, et al. CNS irradiation in pediatric acute myleoid leukemia: Equal results by 12 or 18Gy in studies AML-BFM98 and, 2004. Pediatr Blood Cancer 2011; 57:986-992.
29. Strahm B, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: Results of the EWOG-MDS 98 study. Leukemia 2011; 25:455-462.
30. Mullerweihrich S, Henze G, Jobke A, et al. BFM study, 1975/81 for treatment of Non-Hodgkin lymphoma of high malignancy in children and adolescents. Klin Padiatr 1982; 194:219-225.
31. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999; 94:3294-3306.
32. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report. Blood 2000; 95:416-421.
33. Mullerweihrich S, Beck J, Henze G, et al. BFM study, 1981/83 for treatment of highly malignant Non-Hodgkins lymphoma in children-Results of a therapeutic regimen stratified according to histologic-immunological type and clinical stage. Klin Padiatr 1984; 196:135-142.
34. Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children, adolescents with central nervous system-negative stage, III, or IV lymphoblastic lymphoma. J Clin Oncol 2006; 24:491-499.
35. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule, dose in the treatment of children, adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood 2005; 105:948-958.
36. Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children, adolescents with progressive disease or relapse of lymphoblastic lymphoma: A report from the Berlin-Frankfurt-Muenster group. J Clin Oncol 2009; 27:3363-3369.
37. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell Non-Hodgkin's lymphoma, Burkitt leukemia. J Clin Oncol 2010; 28:3115-3121.
38. Brugieres L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J Clin Oncol 2009; 27:5056-5061.
39. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994; 12:899-908.
40. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001; 97:3699-3706.
41. Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children, adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: A BFM-group study. J Clin Oncol 2011; 29:3065-3071.
42. Schellong G, Bramswig J, Ludwig R, et al. Combined modality treatment in over 200 children with Hodgkins disease-Risk-adapted chemotherapy, low-dose involved field irradiation, selective splenectomy-A report of the cooperative therapy study DAL-HD-82. Klin Padiatr 1986; 198:137-146.
43. Schellong G, Hornigfranz I, Rath B, et al. Reduction of radiation dosage to 20-30Gy in the framework of a combined chemoradiotherapy in childhood Hodgkins disease-A report of the cooperative therapy study DAL-HD-87. Klin Padiatr 1994; 206:253-262.
44. Schellong G, Potter R, Bramswig J, et al. High cure rates, reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. J Clin Oncol 1999; 17:3736-3744.
45. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the late effects study group. J Clin Oncol 2003; 21:4386-4394.
46. Schellong G, Riepenhausen M. Late effects after therapy of F Hodgkin's disease: F Update, 2003/04 on overwhelming post-splenectomy infections and secondary malignancies. Klin Padiatr 2004; 216:364-369.
47. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular, other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children, adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010; 55:1145-1152.
48. Schellong G, Hornig I, Bramswig J, et al. The value of procarbazine in the chemotherapy of Hodgkins-disease-A report of the cooperative therapy study DAL-HD-85. Klin Padiatr 1988; 200:205-213.
49. Mauz-Korholz C, Hasenclever D, Dorffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys, standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: The GPOH-HD, -2002 Study. J Clin Oncol 2010; 28:3680-3686.
50. Jurgens H. Treatment of Ewing sarcoma in children adolescents-A cooperative study of the German Society of Pediatric F Oncology. Klin F Padiatr 1981; 193:254-257.
51. Rosen G, Caparros B, Nirenberg A, et al. Ewings sarcoma-Ten-year experience with adjuvant chemotherapy. Cancer 1981; 47:2204-2213.
52. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewings sarcoma of bone-A 6-year experience of a European Cooperative Trial. Cancer 1988; 61:23-32.
53. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 study: Two randomized trials of Ewing's sarcoma treatment-Cyclophosphamide compared with ifosfamide in standard-risk patients, assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26:4385-4393.
54. Haeusler J, Ranft A, Boelling T, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010; 116:443-450.
55. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314:1600-1606.
56. Bielack S, Juergens H, Jundt G, et al. Osteosarcoma: The COSS experience. Cancer Treat Res 2009; 152:289-308.
57. Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: Experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2003; 21:334-341.
58. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-790.
59. Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: The EURAMOS experience. Cancer Treat Res 2009; 152:339-353.
60. Berthold F, Treuner J, Brandeis WE, et al. Neuroblastoma study NBL 79 of the German-Society for Pediatric Oncology-Report after 2 years. Klin Padiatr 1982; 194:262-269.
61. Berthold F, Burdach S, Kremens B, et al. The role of chemotherapy in the treatment of children with neuroblastoma stage IV-The GPO (German Pediatric Oncology Society) experience. Klin Padiatr 1990; 202:262-269.
62. Berthold F, Hero B. Neuroblastoma-Current drug therapy recommendations as part of the total treatment approach. Drugs 2000; 59:1261-1277.
63. Ladenstein R, Valteau-Couanet D, Brock P, et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: The European HR-NBL1/SIOPEN study. J Clin Oncol 2010; 28:3516-3524.
64. Kushner BH, Cheung NKV, Kramer K, et al. Neuroblastoma, treatment-related myelodysplasia/leukemia: The Memorial Sloan-Kettering experience, a literature review. J Clin Oncol 1998; 16:3880-3889.
65. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, 13-cis-retinoic acid. N Engl J Med 1999; 341:1165-1173.
66. Pritchard J, Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European neuroblastoma study group. Pediatr Blood Cancer 2005; 44:348-357.
67. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 2005; 6:649-658.
68. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002; 346:1047-1053.
69. Simon T, Spitz R, Faldum A, et al. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004; 26:791-796.
70. Hero B, Simon T, Spitz R, et al. Localized infant neuroblastomas often show spontaneous regression: Results of the prospective trials NB95-S and NB97 J Clin Oncol 2008; 26:1504-1510.
71. Oberthuer A, Hero B, Berthold F, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010; 28:3506-3515.
72. Vermeulen J, De Preter K, Naranjo A, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: A retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009; 10:663-671.
73. Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004; 22:3549-3557.
74. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-1334.
75. Lemerle J, Voute PA, Tournade MF, et al. Preoperative versus postoperative radiotherapy, single versus multiple courses of Actinomycin D, in treatment of Wilms tumor-Preliminary results of a controlled clinical trial conducted by International Society of Paediatric Oncology (SIOP). Cancer 1976; 38:647-654.
76. Lemerle J, Voute PA, Tournade MF, et al. Effectiveness of preoperative chemotherapy in Wilms tumor-Results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol 1983; 1:604-609.
77. Tournade MF, Comnougue C, Voute PA, et al. Results of the 6th International Society of Pediatric Oncology Wilms tumor trial, study-A risk-adapted therapeutic approach in Wilms Tumor. J Clin Oncol 1993; 11:1014-1023.
78. Gutjahr P. Results of treatment of Wilms tumors according to a plan (I-76) of the Society of Pediatric Oncology-A retrospective analysis. Klin Padiatr 1980; 192:109-116.
79. Gutjahr P, Schwenger M, Spaar HJ, et al. The influence of preoperative chemotherapy, of radiotherapy in 373 children with Wilms tumor. Dtsch Med Wochenschr 1990; 115:248-253.
80. Dangio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms Tumor-Results of the 3rd national Wilms tumor study. Cancer 1989; 64:349-360.
81. Tournade MF, Com-Nougue C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral, nonmetastatic Wilms' tumor in children older than 6 months: Results of the ninth International Society of Pediatric Oncology Wilms tumor trial, study. J Clin Oncol 2001; 19:488-500.
82. de Kraker J, Graf N, van Tinteren H, et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk, anaplastic Wilms tumour (SIO P 93-01 trial): A randomised controlled trial. Lancet 2004; 364:1229-1235.
83. Graf N, van Tinteren H, Bergeron C, et al. Characteristics, outcome of stage II and III, non-anaplastic Wilms' tumour treated according to the SIOP trial, study 93-01. Eur J Cancer 2012; 48:3240-3248.
84. Pritchard-Jones K, Graf N, Bergeron C, et al. Doxorubicin can be safely omitted from the treatment of stage II/III, intermediate risk histology Wilms tumour: Results of the SIOP WT, 2001 randomised trial, on behalf of the SIOP Renal Tumours Study Group. Pediatr Blood Cancer 2011; 57:741.
85. Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin, etoposide in the treatment of high-risk medulloblastoma, other malignant embryonal tumors of the central nervous system-A phase-II study. J Clin Oncol 1990; 8:330-336.
86. Tait DM, Thorntonjones H, Bloom HJG, et al. Adjuvant chemotherapy for medulloblastoma-The 1st multi-centre control trial of the International Society of Pediatric Oncology (SIOP I). Eur J Cancer 1990; 26:464-469.
87. Kuhl J, Muller L, Berthold F, et al. Preradiation chemotherapy of children, young adults with malignant brain tumors: Results of the German pilot trial HIT88/89. Klin Padiatr 1998; 210:227-233.
88. von Hoff K, Hinkes B, Gerber NU, et al. Long-term outcome, clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer 2009; 45:1209-1217.
89. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352:978-986.
90. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, clinical data of WNT, SHH, Group 3, Group 4 medulloblastomas. Acta Neuropathol 2012; 123:473-484.
91. Lannering B, Rutkowski S, Doz F, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: Results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 2012; 30:3187-3193.
92. Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuroblastoma identifies chromothripsis, defects in neuritogenesis genes. Nature 2012; 483:589-593.
93. Zhang JH, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481:157-163.
94. Zhang JH, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic, epigenetic analyses. Nature 2012; 481:329-334.
95. Rossig C, Juergens H, Berdel WE. New targets targeted drugs for the treatment of cancer: An outlook to pediatric oncology. Pediatr Hematol Oncol 2011; 28:539-555.
96. Vassal G, Geoerger B, Morland B. Is the European pediatric medicine regulation working for children adolescents with cancer? Clin Cancer Res 2013; 19:1215-1315.
97. Kaatsch P, Debling D, Blettner M, Spix C. Second malignant neoplasms after childhood cancer in F Germany-Results from the long-term follow-up of the German Childhood Cancer Registry. Strahlenther Onkol 2009; 185:8-10.
98. Calaminus G, Kaatsch P. Position paper of the Society of Pediatric Oncology Hematology (GPOH) on (long-term) surveillance, (long-term) follow-up, late effect evaluation in pediatric oncology patients. Klin Padiatr 2007; 219:173-178.